Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.9252W HIGH $40.43
Volume
217.63 K
Value Traded
6.67 M
Short % Float
27.32%
-6.82%Week
-33.26%1 Month
-76.73%3 Month
-65.77%6 Month
+51.32%5 Year
+51.32%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
424.36 M
EPS (TTM)
-4.96
P/E Ratio
-
Ent. Value
119.63 M
Total Shares
46.38 M
Float Shares
12.07 M
Insiders
78.28%
Institutions
26.75%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
MPLT Catalyst Timeline
Dated clinical, regulatory and corporate events for MapLight Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MapLight Therapeutics, Inc.
20Total events
8Upcoming
6Tier-1 (high impact)
2026 to 2028Coverage
Upcoming catalysts 2
Event history 10
◆Topline ReadoutML-007C-MAClinical Data
Topline results from Phase 2 ZEPHYR study announced
acute exacerbation of schizophreniasource ↗
▲Topline ReadoutML-007C-MAClinical Data
Positive topline results from Phase 2 ZEPHYR trial
schizophreniasource ↗
▲Primary Endpoint MetML-007C-MAClinical Data
ZEPHYR met primary endpoint with significant PANSS improvement
schizophreniasource ↗
▲Secondary Endpoint DataML-007C-MAClinical Data
ZEPHYR cognitive improvement on prespecified secondary endpoint
schizophreniasource ↗
▲Secondary Endpoint DataML-004Clinical Data
IRIS results reported with positive subgroup analysis
autism spectrum disordersource ↗
Past FDA Catalysts and PDUFA Decisions
How MPLT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$33M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 63%
Micro Cap(rank 415 of 658)
Percentile Rank
MapLight Therapeutics, Inc. faces pipeline headwinds (32/100), with $125M risk-adjusted pipeline value, led by ML-007C-MA in Schizophrenia (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ML-007C-MA Small moleculeNCT07038876 | Schizophrenia | Phase 2 | COMPLETED | 807 | Jun 11, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every MPLT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ML-007C-MA Fast Track | Schizophrenia | Phase 2 | 2026-07-27 | primary: effect size 0.37, ls mean difference vs placebo -4.5, p value 0.015; secondary: cognitive performance effect size 0.51, p value 0.041, cgi s effect size 0.48, p value 0.002, pan ss positive marder factor effect size 0.39, p value 0.012Read More | MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in SchizophreniaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hanson KristopherOfficer (General Counsel) | Sell | -16,509 137,044 held | $11.67 | 09/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MPLT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 0.5 % | 24.58 M | 685.85 K |
MPLT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MPLT ranks across every disease it competes in
Competitive Position is a premium feature
See how MPLT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMPLT News
MPLT▼ -2.2%today
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
MapLight Therapeutics celebrates co-founder Dr. Karl Deisseroth, who received the 2026 Nobel Prize in Physiology or Medicine for his contributions to optogenetics. This recognition highlights the transformative impact of his work on neuroscience and drug discovery. MapLight aims to leverage these insights in developing targeted therapies for CNS disorders, with ongoing clinical trials showing significant progress.
Read more →MPLTMapLight Therapeutics to Participate in Upcoming Investor Conference
MapLight Therapeutics, Inc. has announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14. The management team will present and host one-on-one meetings during the event. The company aims to improve treatments for central nervous system disorders through its innovative discovery platform.
Read more →MPLTSegal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study
Segal Trials has announced its involvement in the Phase 2 ZEPHYR clinical trial, which evaluates MapLight Therapeutics' investigational therapy ML-007C-MA for acute schizophrenia. The trial's topline results were recently disclosed, showcasing the significance of this study in advancing treatment for schizophrenia. Segal Trials expresses pride in contributing to this clinical development.
Read more →MPLTMapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
MapLight Therapeutics has reported positive results from its Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia, paving the way for a Phase 3 trial. The company is also advancing ML-007C-MA in Alzheimer's disease psychosis (ADP), with ongoing enrollment in the Phase 2 VISTA trial and topline results anticipated soon.
Read more →MPLTMapLight Therapeutics Announces $150 Million Private Placement Financing
MapLight Therapeutics has announced a $150 million private placement financing to support its clinical development efforts. The funds will primarily be used for the ongoing VISTA Phase 2 study in Alzheimer's disease psychosis and the ZEPHYR-2 Phase 3 study in schizophrenia. The financing is led by institutional investors and is set to close on August 14, 2026.
Read more →MPLT▼ -72.9%on this news
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial for ML-007C-MA, showing significant improvement in schizophrenia symptoms. The 210/3 mg BID dose met its primary endpoint with a notable reduction in PANSS scores. Additionally, cognitive performance was enhanced in participants with baseline impairments. The drug demonstrated a favorable safety profile, supporting further trials and FDA engagement.
Read more →MPLT▲ +7%on this news· ran to +20% by day 3
MapLight Therapeutics Announces Changes to Board of Directors
MapLight Therapeutics has appointed Martin Babler and Troy Cox to its Board of Directors, succeeding Robert Malenka and Jim Trenkle. Babler will serve on the Audit Committee, while Cox will chair the Nominating and Corporate Governance Committee. The company aims to enhance its strategy for developing therapies for CNS disorders with their leadership.
Read more →MPLTMapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
MapLight Therapeutics announced topline results from the Phase 2 IRIS study of ML-004 in autism spectrum disorder (ASD). While the study did not meet its primary endpoint related to social communication, it showed promising results in reducing irritability among adolescents with moderate to severe baseline irritability. The company plans to discuss the results with the FDA to determine the next steps in clinical development.
Read more →MPLTMapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
MapLight Therapeutics announced its financial results for Q1 2026, highlighting the completion of enrollment in its Phase 2 ZEPHYR trial for schizophrenia and the IRIS trial for autism spectrum disorder, with topline results expected by mid-August 2026. The company reported a cash position of $395.2 million, projected to sustain operations through 2027. However, despite promising clinical developments, the company incurred a net loss of $60.7 million in the quarter, reflecting rising R&D costs and operational expenses. Ongoing trials also include the VISTA trial for Alzheimer's disease psychosis, with expectations for results in the second half of 2027.
Read more →MPLT▼ -6.2%on this news
MapLight Therapeutics to Participate in Upcoming Investor Conferences
MapLight Therapeutics, Inc. announced its participation in two upcoming investor conferences: the 2026 RBCCM Global Healthcare Conference on May 19 and the 2026 Jefferies Global Healthcare Conference on June 3. The management team will present and host one-on-one meetings at both events. The company aims to improve treatments for central nervous system disorders.
Read more →MPLTMapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
MapLight Therapeutics has completed enrollment in its Phase 2 ZEPHYR trial for ML-007C-MA, aimed at treating schizophrenia. Additionally, the final patient visit for the IRIS trial of ML-004 in autism spectrum disorder has been completed. Topline results from both trials are expected by mid-August 2026, highlighting the company's commitment to addressing critical mental health needs.
Read more →MPLT▲ +6%on this news
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MapLight Therapeutics reported its financial results for Q4 and full year 2025, highlighting key developments in its clinical trials. The Phase 2 ZEPHYR trial for schizophrenia is on track for target enrollment by April 2026, while topline results for both the ZEPHYR and IRIS trials are expected in Q3 2026. Additionally, the company received FDA Fast Track designation for ML-007C-MA for Alzheimer's disease psychosis, with a strong cash position to support ongoing operations.
Read more →MPLTMapLight Therapeutics to Participate in Upcoming March 2026 Investor Conferences
MapLight Therapeutics announced its participation in several upcoming investor conferences in March 2026. The events include the Jefferies Biotech on the Beach Summit, the Leerink Global Healthcare Conference, and the Stifel Virtual CNS Forum. The company aims to engage with investors through presentations and one-on-one meetings, highlighting its focus on central nervous system disorders.
Read more →MPLTMapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
MapLight Therapeutics has updated the expected timing for topline results from its Phase 2 ZEPHYR and IRIS studies to Q3 2026. The ZEPHYR trial, focusing on ML-007C-MA for schizophrenia, is enrolling participants rapidly. Additionally, the IRIS trial for autism spectrum disorder has completed enrollment, also targeting results in the same timeframe.
Read more →MPLTxfeff; This presentation and any accompanying oral commentary have been prepared by MapLight Therapeutics, Inc. (“MapLight”, “we,” “us,” “our,” the “Company&
MapLight Therapeutics presented updates on its product candidates during a corporate presentation on January 9, 2026. The company focuses on developing novel treatments for CNS disorders, including schizophrenia and Alzheimer's disease psychosis. Their leading asset includes ML-007C-MA, which is currently in Phase 2 trials with results anticipated in Q3 2026. With approximately $450M in cash, MapLight aims to advance its diversified pipeline despite inherent developmental risks and uncertainties.
Read more →MPLTMapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
MapLight Therapeutics has received Fast Track designation from the FDA for its investigational drug ML-007C-MA, aimed at treating hallucinations and delusions associated with Alzheimer's disease psychosis. This designation highlights the urgent need for effective treatments in this area. The company is currently conducting a Phase 2 clinical trial, expecting to enroll 300 participants and report results in late 2027.
Read more →MPLT▲ +8.4%on this news
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
MapLight Therapeutics reported strong financial results for Q3 2025, highlighted by a successful $296.5 million IPO which positions the company well through 2027. The company is advancing its drug candidates, with Phase 2 ZEPHYR and VISTA trials expected to yield results in 2026 and 2027 respectively for schizophrenia and Alzheimer's disease psychosis. Despite this progress, the company recorded a net loss of $29.4 million in Q3 2025, reflecting ongoing financial challenges associated with clinical trials and regulatory processes.
Read more →MPLTFORM OF SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this " Agreement ") is entered into as of
MapLight Therapeutics, Inc. has entered into a Share Purchase Agreement with an unnamed Investor, proposing the sale of the Company's common stock in conjunction with an upcoming initial public offering (IPO). The Agreement outlines the terms for the Offering, which will occur concurrently with the IPO at the determined IPO price. Additionally, it specifies conditions regarding payment and delivery of shares to the Investor following the IPO Closing Time.
Read more →MPLTMapLight Therapeutics Announces Commencement of Initial Public Offering
MapLight Therapeutics has announced the commencement of its initial public offering (IPO), planning to offer 14,750,000 shares at $17.00 each. Additionally, a concurrent private placement of 476,707 shares is proposed. The registration statement is expected to become effective on October 26, 2025, allowing the company to proceed with its IPO plans.
Read more →About MapLight Therapeutics, Inc.
Headquarters800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
BIOPHARMAWATCH ELITE PLUS
Trade the next MPLT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime